scholarly journals Intravenous Tigecycline Facilitates Cure of Severe Clostridium difficile Infection (CDI) After Failure of Standard Therapy: A Case Report and Literature Review of Tigecycline Use in CDI

2016 ◽  
Vol 3 (2) ◽  
Author(s):  
Bhagyashri D. Navalkele ◽  
Stephen A. Lerner
Keyword(s):  
Septic Shock ◽  
Case Report ◽  
Clostridium Difficile ◽  
Literature Review ◽  
Clostridium Difficile Infection ◽  
Standard Treatment ◽  
Fecal Transplant ◽  
Oral Vancomycin ◽  
Standard Regimen ◽  
Severe Clostridium Difficile Infection

Abstract Standard treatment for severe Clostridium difficile infection (CDI) is oral vancomycin with metronidazole. After failure of this standard regimen, treatment becomes challenging. A young woman treated for septic shock developed CDI. Standard treatment failed and she was ineligible for fecal transplant. Addition of tigecycline to her regimen resulted in cure.

scholarly journals Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S390-S390
Author(s):  
Sunish Shah ◽  
Benjamin Ereshefsky ◽  
Laura Pontiggia ◽  
Michael Cawley
Keyword(s):  
Clostridium Difficile ◽  
Hospital Mortality ◽  
Clostridium Difficile Infection ◽  
Post Infection ◽  
Clinical Cure ◽  
Oral Vancomycin ◽  
End Of Treatment ◽  
Severe Clostridium Difficile Infection ◽  
The Impact ◽  
Length Of Hospitalization

Abstract Background Treatment of severe Clostridium difficile infection (CDI) with oral vancomycin (oVAN) is known to be superior to treatment with metronidazole. However, previous studies have not evaluated the impact on patients when oVAN therapy is delayed after diagnosis or suspicion of severe CDI. Methods This was a single-center, retrospective study of adult patients who were diagnosed with severe CDI as defined by a white blood cell (WBC) count greater than 15,000 cells/mm3. The primary outcome was in-hospital mortality between patients treated initially with oVAN vs. delayed oVAN after metronidazole. Secondary outcomes included clinical cure by day 10, post-infection length of hospitalization, the time to resolution of leukocytosis and renal function at the end of treatment. Leukocytosis was defined as a WBC greater than 12,000 cells/mm3. Patients were excluded if they received oVAN for a previous episode of CDI, were receiving treatment for a concurrent infection, were receiving high-dose steroids, or received metronidazole or oVAN within 5 days preceding CDI diagnosis. Results A total of 121 patients were included. Overall, 49% of patients were female and the median age was 67 years old. 101 patients comprised the initial oVAN group, while 20 patients comprised the delayed oVAN group. Baseline demographics did not differ significantly between groups other than the time to initiation of oVAN (0.33 vs. 3.18 days, P < 0.001). There was no significant difference in in-hospital mortality for patients in the initial oVAN treatment group compared with those who had delayed oVAN therapy (5% vs. 15%, P = 0.13). Patients who received oVAN initially experienced a higher rate of clinical cure by day 10 (49.5% vs. 20%, P = 0.02), a shorter median post-infection length of hospitalization (7 days vs. 13 days, P < 0.001), a shorter median time to resolution of leukocytosis (3.9 days vs. 10.4 days, P = 0.01), and were less likely to have an end of treatment serum creatinine greater than 1.5 times their baseline (8.7% vs. 29.4%, P = 0.03). Conclusion Patients who receive oVAN as their initial treatment for severe CDI have improved clinical outcomes compared with those initially treated with metronidazole. Disclosures All authors: No reported disclosures.

scholarly journals Oral teicoplanin for successful treatment of severe refractory Clostridium difficile infection

2015 ◽  
Vol 9 (10) ◽  
pp. 1062-1067 ◽  
Author(s):  
Natasa Popovic ◽  
Milos Korac ◽  
Zorica Nesic ◽  
Branko Milosevic ◽  
Aleksandar Urosevic ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Combination Therapy ◽  
Clostridium Difficile Infection ◽  
Clinical Cure ◽  
Oral Vancomycin ◽  
Clinical Center ◽  
Significant Difference ◽  
Cure Time ◽  
Severe Clostridium Difficile Infection ◽  
One Year

Introduction: Clostridium difficile is the leading cause of hospital-acquired diarrhoea. There is no defined protocol for treating severe Clostridium difficile infection (CDI) refractory to vancomycin or vancomycin and metronidazole combination therapy. The aim of this study was to evaluate the rate of clinical cure, time to resolution of diarrhoea and recurrence rate in patients with severe refractory CDI treated with oral teicoplanin. Methodology: A one-year prospective study was carried out in the Clinic for Infectious and Tropical Diseases, Clinical Center Serbia. Patients with severe and complicated CDI who failed to respond to oral vancomycin and intravenous metronidazole combination therapy were enrolled. They were given oral teicoplanin 100 mg bi-daily. Patients were followed for recurrence for eight weeks. Results: Nine patients with a mean age of 70.8±9.4 years were analyzed. All patients had pseudomembranous colitis, and five had complicated disease. In four patients intracolonic delivery of vancomycin was also performed in addition to oral vancomycin and intravenous metronidazole prior to initiating teicoplanin, but without improvement. After teicoplanin initiation all patients achieved clinical cure. The mean time to resolution of diarrhoea after teicoplanin introduction was 6.3±4.5 days. There was no statistically significant difference in time to resolution of diarrhoea according to initial leucocyte count, age over 65 years, the presence of ileus, complicated disease and the use of concomitant antibiotic therapy (p = 0.652, 0,652, 0.374, 0.374, and 0,548, respectively). None of the patients experienced recurrence. Conclusions: Oral teicoplanin might be a potential treatment for severe and complicated refractory CDI, but further studies are required.

Sign in / Sign up

Export Citation Format

Share Document